Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TARS · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortTarsus Pharmaceuticals, Inc. is loss-making, burns cash and holds more cash than debt, with revenue growing (+146.7% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -15.7% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -14.7% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -23.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -13.5% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.85× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.21× | 99/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -7.94× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.84 | 45/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -4.9% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 4 | 17/100 |
| Revenue growth volatility | 473.1% | 0/100 |
| Operating margin volatility | 341.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 159.5% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 57 | 26 | 17 | 183 | 451 |
| Research & development | 42 | 43 | 50 | 53 | 64 |
| Selling, general & admin | – | 45 | 109 | 237 | 427 |
| Operating income | (12) | (63) | (143) | (121) | (71) |
| Interest expense | 0 | 2.2 | 3.3 | 7.8 | 8.9 |
| Pre-tax income | (14) | (62) | (136) | (116) | (64) |
| Income tax | 0.1 | (0) | 0 | 0 | 2.1 |
| Net income | (14) | (62) | (136) | (116) | (66) |
| Diluted EPS | −$0.67 | −$2.52 | −$4.62 | −$3.07 | −$1.59 |
| Diluted shares (millions) | 21 | 25 | 29 | 38 | 42 |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
2.84 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026